摘要
目的探讨甘露聚糖肽联合顺铂腔内灌注辅助治疗腺癌性胸腹水的临床疗效。方法选择我院2012年5月至2014年5月期间收治的腺癌性胸腹水患者共130例作为研究对象并分为两组。对照组患者(n=63)仅采用顺铂腔内灌注治疗,而观察组患者(n=67)则在对照组基础上联合甘露聚糖肽治疗。比较两种方法的近期疗效及毒副作用情况。结果观察组的临床总有效率为95.52%,显著高于对照组的80.95%,差异具有统计学意义(P<0.05);而观察组不良反应率为16.42%,对照组则为15.87%,两组间比较差异不具有统计学意义(P>0.05)。结论甘露聚糖肽联合顺铂腔内灌注辅助治疗腺癌性胸腹水的临床疗效显著,并且安全性高,值得在临床上推广使用。
Objective To explore the clinical efficacy of mannatide combined with cisplatin intracavitary in the adjuvant treatment of adenocarcinoma ascites. Methods 130 cases of adenocarcinoma ascites patients were selected in our hospital from May 2012 to May 2014 as the research subjects and were divided into two groups. The patients in the control group （n=63） were only treated with cisplatin intravesical infusion;while the patients in the observation group （n=67） were treated with extra mannatide. Situations such as efficacy and side effects of the two methods were compared. Results The clinical total effective rate of the observation group was 95. 52%, significantly higher than that of the control group, which was 80. 95%. The difference was statistically significant （ P〈0. 05）, the adverse reaction rate of the observation group was 16. 42%, while that of the control group was 15. 87%, with no signifi-cant difference between the two groups （P〉0. 05）. Conclusions The efficacy of mannatide combined with cisplatin intracavitary in the adjuvant treatment of cancer ascites is good and safe, which should be introduced in clinical practice.
出处
《辽宁医学院学报》
CAS
2014年第6期29-30,共2页
Journal of Liaoning Medical University (LNMU) Bimonthly
关键词
顺铂
腺癌性胸腹水
腔内灌注
疗效
不良反应
cisplatin adenocarcinoma ascites intravesical instillation efficacy adverse reactions
